Barw Barw Medical Journal 2960-1959 2023 05 31 Cardiopulmonary Complications Following COVID-19 Vaccinations: A Systematic Review 10.58742/bmj.v1i2.25 eng Bnar J. Hama Amin Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. bnar.amin@gmail.com Dana H. Mohammed Saeed College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. dana.saeed@gamil.com Hadi Mohammed Abdullah Faruq Medical City. Sulaimani, Kurdistan,Iraq. hadi.abdullah@gmail.com Zana H. Mahmood University Of Human Development, Sulaimani,Kurdistan, Iraq.. zana.mahmood@gmail.com Karokh Fadhil Hamahussein Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. karokh.hussein@gmail.com Hussein M. Hamasalih Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. hussein.hama@gmail.com Sabah Jalal Hasan Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. sabah.jalal@gmail.com Sanaa O. Karim College of Nursing, University of Sulaimani, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. sanaa.karim@gmail.com Marwan N. Hassan Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. marwan.nasih12@gmail.com Fahmi H. Kakamad College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. fahmi.hussein@univsul.edu.iq Berun A. Abdalla Smart Health Tower, Scientific Affairs Department, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. berun.anwer95@gmail.com Fakher Abdullah Kscien Organization for Scientific Research (Europe office), Verboomstraat 175b, 3082 jj Rotterdam, Netherlands. fakherabdullah1976@gmail.com Hiwa O. Abdullah Kscien Organization for Scientific Research (Middle East office), Hamid Str, Azadi Mall, Sulaimani, Kurdstan, Iraq. hiewaom96@gmail.com Jihad Ibrahim Hama Research Center, University of Halabja, Halabja, Iraq. jihad.hama@gmail.com Sasan Mohammed Ahmed Smart Health Tower, Madam Mitterrand Street, Sulaimani, Kurdistan, Iraq. sasan0751@gmail.com Shvan H. Mohammed Kscien Organization for Scientific Research (Middle East office), Hamid Str, Azadi Mall, Sulaimani, Kurdstan, Iraq. shvanh80@gmail.com 2023 04 20 Abstract Introduction Clinical trials of COVID-19 vaccines were insufficient to detect uncommon adverse outcomes that are crucial for risk-benefit analyses and informing clinical practice post-vaccination. As a result, detection of infrequent adverse events has become a global research priority. The current study aims to estimate the rate of cardiopulmonary complications associated with COVID-19 vaccination. Methods Two databases and one search engine were explored to identify English language-related studies published up to January 2023. Results The literature search turned up a total of 3974 relevant studies. Of them, 37 articles matched the inclusion criteria. Overall, seven studies from the United States. The mean age of patients was 25 years and about 77% of them were male. The most common reported consequence was inflammatory heart disease (myo-peri-cariditis), followed by pulmonary embolism (17%), and myocardial infarction (5%). The majority of complications were reported following mRNA COVID-19 vaccinations, particularly following the administration of the second dose. Pfizer has a slightly higher risk of cardiac complications following vaccination (4.1 per 100000 persons) than Moderna (3.7 per 100,000 persons). Conclusion Although cardiopulmonary complications associated with COVID-19 vaccinations are uncommon, they can be life-threatening. Therefore, more large-scale observational studies and review articles of those studies are strongly recommended.